Home/Filings/4/0000899243-21-018115
4//SEC Filing

Longwood Fund III, L.P. 4

Accession 0000899243-21-018115

CIK 0001785530other

Filed

May 3, 8:00 PM ET

Accepted

May 4, 4:30 PM ET

Size

16.2 KB

Accession

0000899243-21-018115

Insider Transaction Report

Form 4
Period: 2021-05-04
Transactions
  • Conversion

    Common Stock

    2021-05-04+355,9551,427,082 total(indirect: See footnote)
  • Conversion

    Series A Preferred Stock

    2021-05-049,285,7140 total(indirect: See footnote)
    Common Stock (1,071,127 underlying)
  • Purchase

    Common Stock

    2021-05-04$16.00/sh+250,000$4,000,0001,677,082 total(indirect: See footnote)
  • Conversion

    Series B Preferred Stock

    2021-05-043,085,8110 total(indirect: See footnote)
    Common Stock (355,955 underlying)
  • Conversion

    Common Stock

    2021-05-04+1,071,1271,071,127 total(indirect: See footnote)
Transactions
  • Purchase

    Common Stock

    2021-05-04$16.00/sh+250,000$4,000,0001,677,082 total(indirect: See footnote)
  • Conversion

    Series B Preferred Stock

    2021-05-043,085,8110 total(indirect: See footnote)
    Common Stock (355,955 underlying)
  • Conversion

    Common Stock

    2021-05-04+1,071,1271,071,127 total(indirect: See footnote)
  • Conversion

    Common Stock

    2021-05-04+355,9551,427,082 total(indirect: See footnote)
  • Conversion

    Series A Preferred Stock

    2021-05-049,285,7140 total(indirect: See footnote)
    Common Stock (1,071,127 underlying)
Footnotes (3)
  • [F1]On May 4, 2021, the Series A Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
  • [F2]These securities are held of record by Longwood Fund III, L.P. ("Longwood III"). Longwood Fund III GP, LLC ("Longwood III GP") is the general partner of Longwood III. Voting, investment and dispositive decisions at Longwood III GP with respect to the securities held by Longwood III are made by an investment committee comprised of Christoph Westphal, Richard Aldrich and John Lawrence (collectively, the "IC Members"). Longwood III GP and each of the IC Members may be deemed to share voting, investment and dispositive power over the securities held by Longwood III and as a result may be deemed to have beneficial ownership over such securities. Longwood III GP and each of the IC Members disclaims beneficial ownership over the securities held by Longwood III, except to the extent of their respective pecuniary interests therein.
  • [F3]On May 4, 2021, the Series B Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.

Issuer

Werewolf Therapeutics, Inc.

CIK 0001785530

Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001640546

Filing Metadata

Form type
4
Filed
May 3, 8:00 PM ET
Accepted
May 4, 4:30 PM ET
Size
16.2 KB